Lung cancer causes the largest number of cancer-related deaths in the world. Most (85%) of
lung cancers are classified as non-small-cell lung cancer (NSCLC) and small-cell lung …

Lung cancer is the leading cause of cancer deaths, with small cell lung cancer (SCLC)
representing the most aggressive subtype. Standard treatments have not changed in …

Small-cell lung cancer (SCLC) is a highly aggressive subtype of lung cancer with limited
treatment options. CD47 is a cell-surface molecule that promotes immune evasion by …

Small cell lung cancer (SCLC) is a recalcitrant, aggressive neuroendocrine-type cancer for
which little change to first-line standard-of-care treatment has occurred within the last few …

Lung cancer accounts for most cancer-related deaths worldwide and has an overall 5-year
survival rate of~ 15%. Cell lines have played important roles in the study of cancer biology …

Using unbiased kinase profiling, we identified protein kinase A (PKA) as an active kinase in
small cell lung cancer (SCLC). Inhibition of PKA activity genetically, or pharmacologically by …

Introduction SCLC is the most aggressive subtype of lung cancer, and though most patients
initially respond to platinum-based chemotherapy, resistance develops rapidly …

Despite favorable responses to initial therapy, small-cell lung cancer (SCLC) relapse occurs
within a year and exhibits resistance to multiple drugs. Because of limited accessibility of …

Patient-derived xenograft (PDX) models are increasingly being used in oncology drug
development because they offer greater predictive value than traditional cell line models …

Background SCLC has limited treatment options and inadequate preclinical models.
Promising activity of arsenic trioxide (ASO) recorded in conventional preclinical models of …